I apologize for linking to a previous post of mine if not proper etiquette. I am not expecting anything, apart from new information this summer in regards to the Mirror trial, to move the stock needle substantially one way or the other...especially news regarding a phase 1 trial in the Midfle East. If the results from a pivotal phase 3 trial show no benefit, we could be in for some very challenging times. However, if those results show the improvement we are expecting ( and previous studies have already confirmed significant benefit to existing treatments without compromising the safety of patients ) then the sock will climb. This needs to be on substantive public information, not on speculation. Being an investor that is in this for the very long-haul and the big payout, storms of daily ups/downs are easy to weather.